This is an automatically translated article.
Getoxatin medicine 100mg/50ml is prepared as a concentrated solution for infusion, the main ingredient is Oxaliplatin. The drug is indicated in the treatment of advanced colon - rectal cancer.
1. Uses of Getoxatin 100mg/50ml
1ml of Getoxatin 100mg/50ml contains Oxaliplatin 2mg and enough distilled water for injection. Oxaliplatin is an antineoplastic agent belonging to a new class of platinum compounds, consisting of atomic platinum combined with DCAH and an oxalate group. Studies have shown that Oxaliplatin derivatives interact with DNA, creating crosslinks in and out of the cytoplasmic network, leading to disruption of DNA synthesis, producing cytotoxic and anticancer effects. .
Indications for use of Getoxatin 100mg/50ml: In combination with 5-fluorouracil/leucovorin for:
Supportive treatment of stage III colon cancer (after resection of the primary tumor); Treatment of metastatic colorectal cancer. Contraindications to the use of Getoxatin 100mg/50ml:
Patients with a history of allergy to Oxaliplatin; Breastfeeding mothers; Patients with marrow failure; Patients with peripheral neuropathy have dysfunction before using the first course; Patients with severe renal impairment (Clcr < 30ml/min).
2. How to use and dose Getoxatin 100mg/50ml
How to use: Oxaliplatin is used intravenously. Oxaliplatin is dissolved in 250 - 500 ml of 5% dextrose solution to achieve a concentration of 0.2 mg/ml - 2 mg/ml, given by infusion into a central or peripheral vein over 2 - 6 hours, always before infusion 5 -fluorouracil. In case the patient has extravasation, stop the tradition immediately.
Getoxatin 100mg/50ml solution should be used immediately. After dilution, the drug solution is stable for 24 hours at 2 - 8°C and for 6 hours at 25°C. Sensory examination should be performed before using the drug, only use if the solution is clear and does not contain cloudy particles.
Dosage:
Dosage in adults:
Recommended dose in adjuvant therapy: 85mg/m2 body intravenously, repeated every 2 weeks for 12 courses of treatment (12 months); Recommended dose in the treatment of metastatic colorectal cancer: 85mg/m2 body intravenously, repeated every 2 weeks. Dosage is adjusted according to patient tolerance; Always use Oxaliplatin before taking 5-fluorouracil; Oxaliplatin is mixed in 250 - 500 ml of 5% dextrose solution, infused intravenously over 2 - 6 hours, to give a solution concentration between 0.2mg/ml and 0.7mg/ml (0.7mg/ml is the concentration). the highest level of treatment for Oxaliplatin at a dose of 85mg/m2 of body); Most cases of Oxaliplatin will be treated in combination with a continuous infusion of 5-fluorouracil according to the basic regimen. Oxaliplatin in combination with 5-fluorouracil loading and continuous intravenous infusion regimen is repeated every 2 weeks. Dosage in other subjects:
Patients with renal impairment: Oxaliplatin has not been studied in patients with severe renal impairment. In patients with moderate renal impairment, treatment should be initiated at the usual recommended dose, without dose adjustment in patients with mild renal dysfunction; Hepatic impairment: Oxaliplatin has not been studied in patients with severe hepatic impairment. In clinical studies, no dose adjustment of Getoxatin 100mg/50ml was required in subjects with abnormal liver function tests; Elderly: No dose adjustment is required; Children: There is no indication to use Oxaliplatin for this subject. Overdose: There is currently no antidote for Oxaliplatin. In case of overdose, the side effects of the drug will become severe. The patient should be checked for blood parameters and given symptomatic treatment.
Missed dose: Getoxatin 100mg/50ml is infused by healthcare professionals, so it is rare to miss a dose.
3. Getoxatin 100mg/50ml side effects
Some side effects patients may experience when using Getoxatin 100mg/50ml include:
At the injection site: Reactions at the injection site (extravascular can cause pain and inflammation at the injection site). , which can cause discomfort, especially when Oxaliplatin is infused through a peripheral vein); Autonomic Nervous System: Facial flushing; Systemic: Fever, fatigue, allergic reactions (skin rash, urticaria, rhinitis, conjunctivitis, bronchospasm, angioedema, anaphylaxis, hypotension), pain, weight gain, asthenia , chest pain, weight loss, immune allergy, anemia, thrombocytopenia; Central and Peripheral Nervous System: Headache, paresthesia, peripheral sensory neuropathy, dizziness, meningeal irritation, autonomic neuritis, dysarthria; Gastrointestinal, metabolism and nutrition: Diarrhea, nausea, vomiting, stomatitis/mucositis, constipation, stomach pain, anorexia, dyspepsia, hiccups, gastroesophageal reflux, intestinal obstruction, intestinal obstruction, metabolic acidosis, colitis, Clostridium difficile diarrhea; Musculoskeletal system: Back pain, bone pain, joint pain; Blood and lymphatic system: Nosebleeds, thrombophlebitis, hematuria, pulmonary embolism, rectal bleeding; Psychiatric: Depression, insomnia, agitation; Immune system: Infection; Respiratory: Cough, dyspnea, rhinitis, upper respiratory tract infection, pulmonary fibrosis, interstitial lung disease; Skin and subcutaneous tissue: Skin disorders, alopecia, alopecia, flaking of the skin, erythema, rash, excessive sweating; Other senses: Taste disturbance, auditory toxicity, deafness; Kidneys and urinary tract: Urinary retention, frequent and irregular urination; Eyes: Conjunctivitis, astigmatism, temporary loss of vision, optic neuritis, microfield disturbances; Laboratory abnormalities: Anemia, thrombocytopenia, leukopenia, neutropenia, lymphocytopenia, high alkaline phosphatase, high bilirubin, high LDH, abnormal blood sugar, elevated liver enzymes, serum sodium abnormality, hypokalemia, high blood creatinine. Patients should immediately inform their doctor about the side effects encountered when using Getoxatin 100mg/50ml for appropriate intervention and treatment.
4. Be careful when taking Getoxatin 100mg/50ml
Before and while using Getoxatin 100mg/50ml, patients should note:
Oxaliplatin (the main ingredient of Getoxatin 100mg/50ml) is only used in the oncology department, under the supervision of a rich doctor. experience; There is limited information on the safety of the drug in patients with moderate renal impairment, so the benefit/risk balance for the patient should be weighed. In the case of drug use, the patient's renal function should be closely monitored, the dose adjusted according to drug toxicity; Patients with a history of allergy to the active substance platinum should be monitored for symptoms of allergy. If the patient has an anaphylactic-like reaction to Oxaliplatin, the infusion should be discontinued and symptomatic treatment instituted immediately. In case of extravasation, the drug should be discontinued and symptomatic treatment; Oxaliplatin neurotoxicity should be carefully monitored, especially when combined with drugs with specific neurotoxicity. Neurological examination should be performed before each drug infusion, and then periodically; For patients with pharyngo-laryngeal dysesthesia occurring within or several hours after a 2-hour infusion, the next infusion should last for more than 6 hours; Adjust dose according to severity and duration of neurological symptoms (paresthesia, dysesthesia). If symptoms persist for more than 7 days and cause discomfort, the next dose of Oxaliplatin should be reduced from 85 to 65 mg/m2 (treatment of metastases) or to 75 mg/m2 (adjuvant therapy); If paresthesia without neurological impairment persists to the next treatment period, the next dose of Oxaliplatin should be reduced from 95 to 65 mg/m2 (treatment of metastases) or to 75 mg/m2 (adjuvant therapy); If paresthesia is accompanied by impaired neurological function persisting to the next treatment period, Oxaliplatin should be discontinued; If symptoms improve after discontinuation of Oxaliplatin, reintroduction of treatment may be considered. Patients should be informed of peripheral neurosensory syndromes after discontinuing treatment (there are cases of paresthesia persisting for more than 3 years after stopping adjuvant therapy); Getoxatin medicine 100mg/50ml causes gastrointestinal toxicity with symptoms of nausea and vomiting, should be prevented/treated with antiemetics; Diarrhea, vomiting, especially when Oxaliplatin is combined with 5-fluorouracil can cause dehydration, intestinal obstruction, paralytic ileus, metabolic acidosis, hypokalemia and renal failure. If hematologic toxicity occurs with abnormal leukocyte and platelet counts (as recommended), treatment should be withheld until results are normal. Blood tests should be done before starting treatment, before each course of medication; Patients should be informed of the risk of diarrhea, vomiting, stomatitis, mucositis, and neutropenia after combining Oxaliplatin with 5-fluorouracil so that they can promptly notify their doctor and take treatment measures. fit. If stomatitis/mucositis occurs, the next administration should be delayed until these side effects have resolved or the neutrophil count has returned to an appropriate index; When Oxaliplatin is co-administered with 5-fluorouracil, 5-fluorouracil-specific toxicity occurs that will be critical to the dose adjustment of 5-fluorouracil. If grade 4 diarrhea, grade 3 - 4 leukopenia, grade 3 - 4 thrombocytopenia, the dose of Oxaliplatin should be reduced from 85 to 65 mg/m2 (treatment of metastases) or to 75 mg/m2 (adjuvant therapy). combined dose reduction of 5-fluorouracil; In case the patient has a dry cough, shortness of breath, rales in the lungs, infiltrates on chest X-ray, Oxaliplatin should be stopped until further examination, excluding interstitial lung disease; Use caution when using Getoxatin 100mg/50ml in people with liver disease; Oxaliplatin is potentially genotoxic. Therefore, male patients treated with this medicine should not attempt to conceive for 6 months after treatment. At the same time, men should preserve sperm before taking the drug because Oxaliplatin can cause infertility; Women who should not become pregnant during treatment with Oxaliplatin should use an effective method of contraception; Based on preclinical results, Oxaliplatin may cause a variety of negative effects on the fetus. Therefore, Getoxatin 100mg/50ml should not be administered to pregnant women, only benefits and risks should be weighed, agreed to by the patient; Contraindications to the use of Oxaliplatin in lactating women; Using Oxaliplatin increases the risk of dizziness, nausea, vomiting, transient vision loss, ... affecting the ability to drive, operate machinery. Therefore, patients should be careful when driving or operating machinery if taking this medicine. When using Getoxatin 100mg/50ml, patients should follow all instructions and instructions of their doctor to ensure the highest effectiveness in cancer treatment and reduce the risk of dangerous side effects.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
